Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from China Medical System Holdings ( (HK:0867) ) is now available.
China Medical System Holdings has secured exclusive distribution rights in mainland China for Lidoderm-branded lidocaine cataplasms under a new agreement with Teikoku Pharma USA, a subsidiary of Japan’s Teikoku Seiyaku. The partner will handle production and supply, while China Medical System manages sales in the region under an initial 10-year term starting from the product’s first commercial sale.
Lidoderm, a 5% lidocaine topical patch for postherpetic neuralgia that is also used for other peripheral neuropathic pain, was approved in the U.S. in 1999, in Europe in 2007, and in China in 2024. With an estimated 4 million postherpetic neuralgia patients in China and rising incidence among older adults, the deal positions China Medical System to tap a large, under-addressed pain market and deepen its presence in pain management therapies.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings is a pharmaceutical group focused on commercializing branded and innovative drugs in mainland China. The company works with international partners to distribute specialty therapies, particularly in areas such as pain management and other chronic or underserved conditions in the Chinese market.
Average Trading Volume: 4,318,993
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.74B
Find detailed analytics on 0867 stock on TipRanks’ Stock Analysis page.